DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0023705 A1 Roberts Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 20090023705A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0023705 A1 Roberts et al. (43) Pub. Date: Jan. 22, 2009 (54) DROXIDOPA AND PHARMACEUTICAL Publication Classification COMPOSITION THEREOF FOR THE (51) Int. Cl. TREATMENT OF MOOD DISORDERS, SLEEP A 6LX 3/553 (2006.01) DSORDERS ORATTENTION DEFICT A 6LX 3L/95 (2006.01) DSORDERS A 6LX 3L/275 (2006.01) A6II 3/12 (2006.01) A6II 3/445 (2006.01) A6IP 25/20 (2006.01) A6IP 25/24 (2006.01) (75) Inventors: Michael J. Roberts, Charlotte, NC A6IP 25/22 (2006.01) (US); Simon Pedder, Fort Mill, SC A63L/35 (2006.01) (US) A6II 3/44 (2006.01) A 6LX 3/5.375 (2006.01) A63/37 (2006.01) (52) U.S. Cl. .................... 514/211.13: 514/567; 514/565; Correspondence Address: 514/619; 514/676; 514/319; 514/354; 514/239.2: ALSTON & BRD LLP 514/651: 514/646 BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000 (57) ABSTRACT CHARLOTTE, NC 28280-4000 (US) The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of condi tions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions (73) Assignee: Chelsea Therapeutics, Inc. useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyl (21) Appl. No.: 12/116,560 transferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antide (22) Filed: May 7, 2008 pressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotoner Related U.S. Application Data gic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of (60) Provisional application No. 60/916,497, filed on May depression, narcolepsy, insomnia, and Attention Deficit/Hy 7, 2007. peractivity Disorder (AD/HD). Patent Application Publication Jan. 22, 2009 Sheet 1 of 2 US 2009/0023705 A1 250 - 200 150 100 50 Patent Application Publication Jan. 22, 2009 Sheet 2 of 2 US 2009/0023705 A1 O 50 100 150 200 250 300 350 Vehicle Despiramine Entacapone Fluoxetine Wenlafaxine Amitriptyline Droxidopa -- Carbidopa Droxidopa + Carbidopa it Entacapone Droxidopa + Carbidopa -- Fluoxetine Droxidopa + Carbidopa + Venlafaxine Droxidopa + Carbidopa + Amitriptyline FIG. 2 US 2009/0023705 A1 Jan. 22, 2009 DROXDOPA AND PHARMACEUTICAL decisions; Suicidal thoughts or attempts; frequent physical COMPOSITION THEREOF FOR THE complaints (i.e., headache, stomach ache, fatigue); running TREATMENT OF MOOD DISORDERS, SLEEP away or threats of running away from home; hypersensitivity DISORDERS ORATTENTON DEFCIT to failure or rejection; and irritability, hostility, or aggression. DISORDERS In mood disorders, these feelings appear more intense than what a person may normally feel from time to time, and these CROSS-REFERENCE TO RELATED feelings tend to continue over a period of time or interfere APPLICATIONS with an individual’s interest in family, friends, community, or work. 0001. The present application claims priority to U.S. Pro 0006 Various treatments are currently available for mood visional Patent Application No. 60/916,497, filed May 7, disorders. Examples of current treatments include antidepres 2007, which is incorporated herein by reference in its entirety. sant medications, psychotherapy, and family therapy. Three major types of medication are typically used to treat depres FIELD OF THE INVENTION sion: tricyclics, selective serotonin re-uptake inhibitors (SS 0002 The present application is directed to methods of RIs), and monoamine oxidase inhibitors (MAO inhibitors). treatment of various conditions. In particular, the application All three classes of medications are known to have varying is directed to the use of droxidopa, alone or in combination degrees of effectiveness from patient to patient. Moreover, all with one or more additional components, for the treatment of three classes of medications are known to cause varying, various conditions, such as mood disorders, sleep disorders, undesirable side effects. It is estimated that approximately 44 or attention deficit disorders. million Americans experience a mental disorder each year, and mental illnesses are among the most common conditions BACKGROUND affecting health today. Accordingly, there remains a need in 0003 Droxidopa is a known synthetic amino acid precur the art for further pharmaceutical compositions useful in the sor of norepinephrine that is converted directly to norepi treatment of mood disorders, particularly depression. nephrine via the action of dopa decarboxylase (DDC). Droxi 0007 Sleep disorder encompasses a broad range of con dopa is generally used to treat orthostatic hypotension (OH) ditions, including sleep apnea (brief periods while sleeping and can be categorized as an antiparkinsonian agent; how during which breathing stops), insomnia (which includes dif ever, multiple pharmacological activities have been observed ficulty falling asleep or staying asleep, waking too early, or with droxidopa, including the following: (1) it is directly Sleep State Misperception), narcolepsy (an irresistible need converted to 1-norepinephrine by the action of the aromatic to sleep, where sleep attacks lasting from about 30 seconds to L-amino acid decarboxylase which is widely distributed in a about 30 minutes occur during waking hours), and restless leg living body, and thus has an effect of replenishing norepi syndrome (a discomfort in the legs, often sensed while trying nephrine; (2) it has limited permeability through the blood to sleep, which can include crawling, tingling, or prickling brain barrier into the brain; (3) it specifically recovers nore sensation, that can be relieved by moving or stimulating the pinephrine activated nerve functions which have decreased in legs). Sleep disorders are often comorbid with other condi the central and peripheral nervous system; and (4) it shows tions, such as depression, fibromyalgia, and chronic fatigue various actions, as norepinephrine, via the adrenaline recep syndrome. tors in various tissues. 0008 Narcolepsy, in particular, is known to adversely 0004 Mood disorders form a category of mental health affect an individual’s ability to function in daily life. This problems that include all types of depression and are some condition may be classified under the broader term of hyper times called affective disorders. The most common types of Somnia, which encompasses additional sleep attack condi mood disorders include: major depressive disorder, which is tions, such as idiopathic hypersomnia, recurrent hyperSom defined as an at least two-week period of a depressed or nia, and hypersomnia resulting from a medical condition. The irritable mood or a noticeable decrease in interest or pleasure 'sleep attacks' common with narcolepsy can occur at any in usual activities, along with other signs of a mood disorder; time. Such as while working, carrying on a conversation, or dysthymia (dysthymic disorder), which is defined as a even driving a car. The four classic symptoms of narcolepsy chronic, low-grade, depressed or irritable mood for at least are excessive daytime sleepiness; cataplexy (Sudden, brief one year, manic depression (bipolar disorder), which is episodes of muscle weakness or paralysis brought on by defined as at least one episode of a depressed or irritable mood strong emotions such as laughter, anger, Surprise, or antici and at least one period of a manic (persistently elevated) pation); sleep paralysis (paralysis upon falling asleep or wak mood; mood disorder due to a general medical condition ing up); and hypnagogic hallucinations (vivid dreamlike (such as cancer, injuries, infections, and chronic medical images that occur at sleep onset). Disturbed nighttime sleep, illnesses), which can trigger symptoms of depression; and including tossing and turning in bed, leg jerks, nightmares, Substance induced mood disorder, wherein symptoms of and frequent awakenings, may also occur. depression are present due to the effects of medication, drug 0009. There is no known cure for narcolepsy, but some abuse, exposure to toxins, or other forms of treatment. evidence Suggests the condition may be linked to abnormali 0005 Depending upon age and the type of mood disorder ties in cerebral perfusion. See Joo et al., Neuroimage (2005), present, a person may exhibit different symptoms of depres 28(2): p. 410-416, which is incorporated herein by reference. Sion. The following are the most common symptoms of a Excessive daytime sleepiness is typically treated with stimu mood disorder; however, each individual may experience lant drugs, such as methylphenidate (e.g., RITALINR), dex symptoms differently. Symptoms may include: persistent troamphetamine (e.g., DEXTROSTATCR) O feelings of sadness; feeling hopeless or helpless; having low DEXEDRINE(R), methamphetamine (DESOXYNR), pemo self-esteem; feeling inadequate; excessive guilt; feelings of line (CYLERTR), mazindol (SANOREX(R), as well as the wanting to die; loss of interest in usual activities or activities “non-stimulant stimulant modafinil (PROVIGIL(R). Cata once enjoyed; difficulty with relationships; sleep distur plexy and other REM-sleep symptoms are often
Recommended publications
  • Download Product Insert (PDF)

    Download Product Insert (PDF)

    PRODUCT INFORMATION Isocarboxazid Item No. 23625 CAS Registry No.: 59-63-2 Formal Name: 5-methyl-3-isoxazolecarboxylic acid, 2-(phenylmethyl)hydrazide Synonyms: NSC 169893, Ro 5-0831 H N N H MF: C12H13N3O2 FW: 231.3 N O Purity: ≥98% O Supplied as: A solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Isocarboxazid is supplied as a solid. A stock solution may be made by dissolving the isocarboxazid in the solvent of choice. Isocarboxazid is slightly soluble in acetonitrile and chloroform. Description 1 Isocarboxazid is an inhibitor of monoamine oxidase (MAO; IC50 = 4.8 μM for rat brain MAO). It induces a 4-fold increase in tryptamine action in isolated rat fundal strips at a concentration of 50 nM. In vivo, isocarboxazid potentiates tryptamine toxicity (LD50 = 8 mg/kg following subcutaneous administration of 250 mg/kg tryptamine). It inhibits 90% of MAO activity in isolated rat hearts and reduces cardiomegaly induced by isoproterenol (Item No. 15592) in rats at a dose of 20 mg/kg.2 Oral administration of isocarboxazid (10 mg/kg) increases levels of dopamine and norepinephrine and reduces levels of the monoamine metabolites DOPAC, homovanillic acid (HVA; Item No. 20877), and 5-hydroxy indole-3-acetic acid (5-HIAA; Item No. 22889) by 43, 32, and 28%, respectively, in mouse brain.3 Formulations containing isocarboxazid have been used for the treatment of minor depression.4 References 1. Maxwell, D.R., Gray, W.R., and Taylor, E.M. Relative activity of some inhibitors of mono-amine oxidase in potentiating the action of tryptamine in vitro and in vivo.
  • Studies on the Metabolism and Toxicity of Hydrazine in The~Rat~

    Studies on the Metabolism and Toxicity of Hydrazine in The~Rat~

    STUDIES ON THE METABOLISM AND TOXICITY OF HYDRAZINE IN THE~RAT~ Andrew Michael Jenner, B.Sc. Submitted to the University of London for the examination of the degree for Doctor of Philosophy, 1992 Toxicology Department The School of Pharmacy Brunswick Square London ProQuest Number: U068521 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest U068521 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 ACKNOWLEDGEMENTS I would like to express my sincere appreciation to my supervisor Dr. John Timbrell for his invaluable advice, guidance and support. Many people have assisted the progress of my studies in a wide variety of ways, including everyone who has worked alongside me in the Toxicology Unit, both past and present. Particular thanks go to Simon (ET) for his critical eye and mutual, down to earth Yorkshire mentality and also to Cathy for her heartening encouragement. I would also like to thank Dr. Alan Boobis for his assistance in obtaining human liver samples and to the USAF for funding this project. Finally I would like to recognise Jacqui for her designs, Maria for her typing, Justina for her continuous care and support and to my mum and dad for their understanding and my much appreciated conveyance through life.
  • Ayahuasca: Spiritual Pharmacology & Drug Interactions

    Ayahuasca: Spiritual Pharmacology & Drug Interactions

    Ayahuasca: Spiritual Pharmacology & Drug Interactions BENJAMIN MALCOLM, PHARMD, MPH [email protected] MARCH 28 TH 2017 AWARE PROJECT Can Science be Spiritual? “Science is not only compatible with spirituality; it is a profound source of spirituality. When we recognize our place in an immensity of light years and in the passage of ages, when we grasp the intricacy, beauty and subtlety of life, then that soaring feeling, that sense of elation and humility combined, is surely spiritual. The notion that science and spirituality are somehow mutually exclusive does a disservice to both.” – Carl Sagan Disclosures & Disclaimers No conflicts of interest to disclose – I don’t get paid by pharma and have no potential to profit directly from ayahuasca This presentation is for information purposes only, none of the information presented should be used in replacement of medical advice or be considered medical advice This presentation is not an endorsement of illicit activity Presentation Outline & Objectives Describe what is known regarding ayahuasca’s pharmacology Outline adverse food and drug combinations with ayahuasca as well as strategies for risk management Provide an overview of spiritual pharmacology and current clinical data supporting potential of ayahuasca for treatment of mental illness Pharmacology Terms Drug ◦ Term used synonymously with substance or medicine in this presentation and in pharmacology ◦ No offense intended if I call your medicine or madre a drug! Bioavailability ◦ The amount of a drug that enters the body and is able to have an active effect ◦ Route specific: bioavailability is different between oral, intranasal, inhalation (smoked), and injected routes of administration (IV, IM, SC) Half-life (T ½) ◦ The amount of time it takes the body to metabolize/eliminate 50% of a drug ◦ E.g.
  • The Effects of Phenelzine and Other Monoamine Oxidase Inhibitor

    The Effects of Phenelzine and Other Monoamine Oxidase Inhibitor

    British Journal of Phammcology (1995) 114. 837-845 B 1995 Stockton Press All rights reserved 0007-1188/95 $9.00 The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver 12 imidazoline-preferring receptors Regina Alemany, Gabriel Olmos & 'Jesu's A. Garcia-Sevilla Laboratory of Neuropharmacology, Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, E-07071 Palma de Mallorca, Spain 1 The binding of [3H]-idazoxan in the presence of 106 M (-)-adrenaline was used to quantitate 12 imidazoline-preferring receptors in the rat brain and liver after chronic treatment with various irre- versible and reversible monoamine oxidase (MAO) inhibitors. 2 Chronic treatment (7-14 days) with the irreversible MAO inhibitors, phenelzine (1-20 mg kg-', i.p.), isocarboxazid (10 mg kg-', i.p.), clorgyline (3 mg kg-', i.p.) and tranylcypromine (10mg kg-', i.p.) markedly decreased (21-71%) the density of 12 imidazoline-preferring receptors in the rat brain and liver. In contrast, chronic treatment (7 days) with the reversible MAO-A inhibitors, moclobemide (1 and 10 mg kg-', i.p.) or chlordimeform (10 mg kg-', i.p.) or with the reversible MAO-B inhibitor Ro 16-6491 (1 and 10 mg kg-', i.p.) did not alter the density of 12 imidazoline-preferring receptors in the rat brain and liver; except for the higher dose of Ro 16-6491 which only decreased the density of these putative receptors in the liver (38%). 3 In vitro, phenelzine, clorgyline, 3-phenylpropargylamine, tranylcypromine and chlordimeform dis- placed the binding of [3H]-idazoxan to brain and liver I2 imidazoline-preferring receptors from two distinct binding sites.
  • FROM the LITERATURE PET in Assessment of Abuse Potential

    FROM the LITERATURE PET in Assessment of Abuse Potential

    NEWSLINE FROM THE LITERATURE Each month the editor of Newsline drug radafaxine ([2S,3S])-2-[3-chlo- in the putamen. The authors con- selects articles on diagnostic, thera- rophenyl]-3,5,5,-trimethyl-2-mor- cluded that these and other data “sug- peutic, research, and practice issues pholinol hydrochloride). Radafaxine gest that the neurodegenerative from a range of international publica- is a potent metabolite of bupropion process in PD follows a negative ex- tions. Most selections come from out- that is being evaluated both as a treat- ponential course and slows down side the standard canon of nuclear ment for depression and for possible with increasing symptom duration, medicine and radiology journals. Note use in treatment of obesity. The study contradicting the long-latency hypo- that although we have divided the ar- included 8 healthy men who under- thesis of PD.” ticles into diagnostic and therapeutic went 11C-cocaine PET imaging at 1, Archives of Neurology categories, these lines are increasingly 4, 8, and 24 hours after radafaxine blurred as nuclear medicine capabili- administration. The authors found ties rapidly expand. Many diagnostic that DAT blockade by radafaxine PET and rCBF in Cocaine capabilities are now enlisted in direct was slow, reaching 11% at 1 hour Use Disorder support of and, often, in real-time con- and a peak blockade of 22% at 4 In an article e-published ahead of junction with, therapies. These briefs hours. The maximum blockade in print in the March 9 issue of the are offered as a monthly window on the any single subject was 33%.
  • Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion and Pharmacokinetics

    Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion and Pharmacokinetics

    TESI DOCTORAL HUMAN PHARMACOLOGY OF AYAHUASCA JORDI RIBA Barcelona, 2003 Director de la Tesi: DR. MANEL JOSEP BARBANOJ RODRÍGUEZ A la Núria, el Marc i l’Emma. No pasaremos en silencio una de las cosas que á nuestro modo de ver llamará la atención... toman un bejuco llamado Ayahuasca (bejuco de muerto ó almas) del cual hacen un lijero cocimiento...esta bebida es narcótica, como debe suponerse, i á pocos momentos empieza a producir los mas raros fenómenos...Yo, por mí, sé decir que cuando he tomado el Ayahuasca he sentido rodeos de cabeza, luego un viaje aéreo en el que recuerdo percibia las prespectivas mas deliciosas, grandes ciudades, elevadas torres, hermosos parques i otros objetos bellísimos; luego me figuraba abandonado en un bosque i acometido de algunas fieras, de las que me defendia; en seguida tenia sensación fuerte de sueño del cual recordaba con dolor i pesadez de cabeza, i algunas veces mal estar general. Manuel Villavicencio Geografía de la República del Ecuador (1858) Das, was den Indianer den “Aya-huasca-Trank” lieben macht, sind, abgesehen von den Traumgesichten, die auf sein persönliches Glück Bezug habenden Bilder, die sein inneres Auge während des narkotischen Zustandes schaut. Louis Lewin Phantastica (1927) Agraïments La present tesi doctoral constitueix la fase final d’una idea nascuda ara fa gairebé nou anys. El fet que aquest treball sobre la farmacologia humana de l’ayahuasca hagi estat una realitat es deu fonamentalment al suport constant del seu director, el Manel Barbanoj. Voldria expressar-li la meva gratitud pel seu recolzament entusiàstic d’aquest projecte, molt allunyat, per la natura del fàrmac objecte d’estudi, dels que fins al moment s’havien dut a terme a l’Àrea d’Investigació Farmacològica de l’Hospital de Sant Pau.
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types

    Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types

    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
  • A Graph Convolutional Network Framework for Predicting Multi-Type Drug-Drug Interactions

    A Graph Convolutional Network Framework for Predicting Multi-Type Drug-Drug Interactions

    MTDDI: a graph convolutional network framework for predicting Multi-Type Drug-Drug Interactions YueHua Feng ( [email protected] ) Northwestern Polytechnical University https://orcid.org/0000-0002-3783-1305 Shao-Wu Zhang Northwestern Polytechnical University https://orcid.org/0000-0003-1305-7447 Qing-Qing Zhang Northwestern Polytechnical University https://orcid.org/0000-0002-7931-1834 Chu-Han Zhang Northwestern Polytechnical University https://orcid.org/0000-0002-2897-3918 Jian-Yu Shi Northwestern Polytechnical University https://orcid.org/0000-0002-2303-273X Research article Keywords: Drug-drug interactions (DDIs), multi-type DDIs prediction, graph convolution network (GCN), tensor factorization, deep neural network, multiple relation prediction, similarity regularization Posted Date: April 9th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-397281/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License MTDDI: a graph convolutional network framework for predicting Multi-Type Drug-Drug Interactions Yue-Hua Feng1, Shao-Wu Zhang1*, Qing-Qing Zhang1, Chu-Han Zhang2, Jian-Yu Shi3* 1 Key Laboratory of Information Fusion Technology of Ministry of Education, School of Automation, Northwestern Polytechnical University, Xi’an, 710072, China 2 School of Software, Northwestern Polytechnical University, Xian, 710072, China 3 School of Life Sciences, Northwestern Polytechnical University, Xi’an, 710072, China * Correspondence: [email protected] ; [email protected] Abstract— Although the polypharmacy has both higher therapeutic efficacy and less drug resistance in combating complex diseases, drug-drug interactions (DDIs) may trigger unexpected pharmacological effects, such as side effects, adverse reactions, or even serious toxicity. Thus, it is crucial to identify DDIs and explore its underlying mechanism (e.g., DDIs types) for polypharmacy safety.
  • Les Femmes Peuvent Prendre Du Viagra * Achat De Viagra En

    Les Femmes Peuvent Prendre Du Viagra * Achat De Viagra En

    Viagra est indiquée pour le traitement de la dysfonction érectile masculine. >>> ORDER NOW <<< Les femmes peuvent prendre du viagra Tags: cialis ou viagra acheter vrai ou faux viagra risques avec viagra acheter du viagra sans ordonnance en suisse danger du faux viagra comment bien prendre viagra le prix du viagra en pharmacie au maroc les effets indesirable du viagra que ce que viagra de gaulle contre le viagra achat viagra internet doctissimo commande viagra belgique peut on avoir du viagra en pharmacie sans ordonnance comment prendre sildenafil pfizer nitrates and viagra interaction ordonnance ou pas pour viagra notice demballage viagran quels sont les effets du viagra quelle quantité de viagra prendre peut on acheter viagra en pharmacie sans ordonnance comment avoir le viagra site sur achat viagra nitrates viagra can deadly combination Recession quest ce qui peut remplacer le viagra review am astonishingly forgetful. Some things said caffeine was fine to consume (in drinks, food, etc) while on the med, others said caffeine decreased the effects of the med. Features of this disorder include dysphonia, dysarthria, and loss of pain and temperature over the ipsilateral face and contralateral body. Jeg vil også erklære, at du forlader soap ud. If you feel very bored when waiting for something or someone (a bus, your friend, your kids), distract yourself with a book, magazine, or crossword puzzle. The celexa is longer acting and must build in the system over time in order to work for anxiety. Medscape is the leading online destination for healthcare professionals seeking clinical information. Paxil over time increased my appetite but i think that is because les femmes peuvent prendre du viagra made me tired and lethargic, they did not increase appetite, in fact in the first few months they curbed it right down.
  • Fatal Toxicity of Antidepressant Drugs in Overdose

    Fatal Toxicity of Antidepressant Drugs in Overdose

    BRITISH MEDICAL JOURNAL VOLUME 295 24 OCTOBER 1987 1021 Br Med J (Clin Res Ed): first published as 10.1136/bmj.295.6605.1021 on 24 October 1987. Downloaded from PAPERS AND SHORT REPORTS Fatal toxicity of antidepressant drugs in overdose SIMON CASSIDY, JOHN HENRY Abstract dangerous in overdose, thus meriting investigation of their toxic properties and closer consideration of the circumstances in which A fatal toxicity index (deaths per million National Health Service they are prescribed. Recommendations may thus be made that prescriptions) was calculated for antidepressant drugs on sale might reduce the number offatalities. during the years 1975-84 in England, Wales, and Scotland. The We used national mortality statistics and prescription data tricyclic drugs introduced before 1970 had a higher index than the to compile fatal toxicity indices for the currently available anti- mean for all the drugs studied (p<0-001). In this group the depressant drugs to assess the comparative safety of the different toxicity ofamitriptyline, dibenzepin, desipramine, and dothiepin antidepressant drugs from an epidemiological standpoint. Owing to was significantly higher, while that ofclomipramine, imipramine, the nature of the disease these drugs are particularly likely to be iprindole, protriptyline, and trimipramine was lower. The mono- taken in overdose and often cause death. amine oxidase inhibitors had intermediate toxicity, and the antidepressants introduced since 1973, considered as a group, had significantly lower toxicity than the mean (p<0-001). Ofthese newer drugs, maprotiline had a fatal toxicity index similar to that Sources ofinformation and methods of the older tricyclic antidepressants, while the other newly The statistical sources used list drugs under their generic and proprietary http://www.bmj.com/ introduced drugs had lower toxicity indices, with those for names.
  • Phenylmorpholines and Analogues Thereof Phenylmorpholine Und Analoge Davon Phenylmorpholines Et Analogues De Celles-Ci

    Phenylmorpholines and Analogues Thereof Phenylmorpholine Und Analoge Davon Phenylmorpholines Et Analogues De Celles-Ci

    (19) TZZ __T (11) EP 2 571 858 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 265/30 (2006.01) A61K 31/5375 (2006.01) 20.06.2018 Bulletin 2018/25 A61P 25/24 (2006.01) A61P 25/16 (2006.01) A61P 25/18 (2006.01) (21) Application number: 11723158.9 (86) International application number: (22) Date of filing: 20.05.2011 PCT/US2011/037361 (87) International publication number: WO 2011/146850 (24.11.2011 Gazette 2011/47) (54) PHENYLMORPHOLINES AND ANALOGUES THEREOF PHENYLMORPHOLINE UND ANALOGE DAVON PHENYLMORPHOLINES ET ANALOGUES DE CELLES-CI (84) Designated Contracting States: • DECKER, Ann Marie AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Durham, North Carolina 27713 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hoeger, Stellrecht & Partner Patentanwälte mbB (30) Priority: 21.05.2010 US 347259 P Uhlandstrasse 14c 70182 Stuttgart (DE) (43) Date of publication of application: 27.03.2013 Bulletin 2013/13 (56) References cited: WO-A1-2004/052372 WO-A1-2008/026046 (73) Proprietors: WO-A1-2008/087512 DE-B- 1 135 464 • Research Triangle Institute FR-A- 1 397 563 GB-A- 883 220 Research Triangle Park, North Carolina 27709 GB-A- 899 386 US-A1- 2005 267 096 (US) • United States of America, as represented by • R.A. GLENNON ET AL.: "Beta-Oxygenated The Secretary, Department of Health and Human Analogues of the 5-HT2A Serotonin Receptor Services Agonist Bethesda, Maryland 20892-7660 (US) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopro pane", JOURNAL OF MEDICINAL CHEMISTRY, (72) Inventors: vol.